within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07F_AntidiarrhealMicroorganisms.A07FA03_EscherichiaColi;

model EscherichiaColi
  extends Pharmacolibrary.Drugs.ATC.A.A07FA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A07FA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>0</td></tr></table><p>Escherichia coli (E. coli) Nissle 1917 is a probiotic preparation used in some countries for the treatment and prevention of gastrointestinal disorders such as ulcerative colitis, irritable bowel syndrome, and infectious diarrhea. This drug is composed of live, non-pathogenic E. coli bacteria and is classified under intestinal anti-inflammatory/anti-infective microorganisms. It is not universally approved and is not used in the United States, but is utilized in a number of European and other countries for gastrointestinal disease management.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies exist as E. coli Nissle 1917 is a live probiotic microorganism and not absorbed systemically. Thus, typical pharmacokinetic parameters such as absorption, distribution, metabolism, and elimination are not applicable.</p><h4>References</h4><ol><li><p>Kim, P, et al., &amp; Garofolo, PM (2024). Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. <i>The Lancet. Infectious diseases</i> 24(12) 1319–1332. DOI:<a href=&quot;https://doi.org/10.1016/S1473-3099(24)00424-9&quot;>10.1016/S1473-3099(24)00424-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39134085/&quot;>https://pubmed.ncbi.nlm.nih.gov/39134085</a></p></li><li><p>Wang, H, et al., &amp; Yang, F (2022). Influence of Escherichia coli endotoxemia on danofloxacin pharmacokinetics in broilers following single oral administration. <i>Journal of veterinary pharmacology and therapeutics</i> 45(2) 220–225. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13035&quot;>10.1111/jvp.13035</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34882308/&quot;>https://pubmed.ncbi.nlm.nih.gov/34882308</a></p></li><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2022). Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> 82(5) 533–557. DOI:<a href=&quot;https://doi.org/10.1007/s40265-022-01688-1&quot;>10.1007/s40265-022-01688-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35294769/&quot;>https://pubmed.ncbi.nlm.nih.gov/35294769</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end EscherichiaColi;
